Regulation of HIV-1 Transcription by CDK2
Regulation of HIV-1 Transcription by CDK2
批准号:
7795194
负责人:
SERGEI NEKHAI
金额:
$25.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2012-03-31
关键词:
AffectBindingBiochemicalBiological AssayC-terminalCYC 202Cell CycleCell ExtractsCellsComplexCultured CellsCyclin EDataDevelopmentDrug resistanceEducational workshopElementsFractionationFundingGenetic TranscriptionGrantHIVHIV-1Hela CellsIn VitroInternationalKineticsLaboratoriesMediatingMolecular ModelsMutateMutationNuclear ExtractPharmaceutical PreparationsPhosphorylationPhosphorylation SitePhosphotransferasesPhysiologicalPositive Transcriptional Elongation Factor BProvirusesPublishingRNARNA InterferenceRNA Polymerase IIRecombinantsRecruitment ActivityRegulationResearchResearch PersonnelResearch Project GrantsResistanceRoleSerineSmall Interfering RNAT-LymphocyteTherapeuticTransactivationUbiquitinationUniversitiesVP 16ViralVirusWritingcyclin T1designhealth disparityhistone acetyltransferaseinhibitor/antagonistmeetingsmolecular modelingmutantprogramsreconstitutionresponseskillstat Protein
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant)
Project Research Objectives: The emergence of drug-resistant HIV-1 strains presents a challenge for the design of new drugs. Targeting host cell factors involved in the regulation of HIV-1 replication might be one way to overcome the resistance of HIV-1 to anti-viral agents. We hypothesize that CDK2 has a regulatory role in HIV transcription. We propose that the mechanism whereby CDK2 regulates HIV-1 transcription may include (1) phosphorylation of Tat by CDK2 that may enhance interaction of P-Tat with cyclin T1 or histone acetyltransferases and recruitment of co-activators to HIV-1 transcription complex, or ubiquitination of P-Tat that may enhance its transcriptional activity or its stability; and (2) CDK2/cyclin E-mediated phosphorylation of RNAPII CTD heptapeptide repeats. In specific aim 1, we will investigate the physiological importance of Tat phosphorylation for HIV-1 transcription. Specifically, we will mutate Ser16 and Ser46 residues of tat in the pNL4-3 provirus and determine the kinetics of replication of mutant viruses and analyze Tat phosphorylation during viral replication. We will also analyze the effect of mutations of Tat Ser16 and Ser46 residues on Tat binding to P-TEFb and TAR RNA; to histone acetyltransferases and whether phosphorylation of Tat facilitates its ubiquitination or affects the stability of Tat protein. In specific aim 2, we will analyze kinetics of Tat phosphorylation by CDK2 and interaction of phosphorylated Tat with transcriptional co-activators. We will study the kinetics of the phosphorylation of wild and mutant Tat by CDK2/cyclin E in vitro; interaction of phosphorylated Tat with transcriptional co-activators and interaction of Tat with CDK2/cyclin E using molecular modeling. In specific aim 3, we will determine the mechanism whereby CDK2 influences HIV-1 transcription. We will investigate if inhibition of CDK2 affects transcription induced by artificially targeted cyclin T1 or VP16 and whether inhibition of CDK2 affects cellular activity of CDK9. We will determine if phosphorylation of Tat by CDK2 promotes the association of CDK2 with RNAPII transcription complex and phosphorylation of CTD during HIV-1 transcription in vitro and in cultured cells.
Project Developmental Objectives: (1) develop into an independent investigator by establishing my own laboratory using SC1 funding and by presenting my research at SCORE-funded and international meetings; (2) prepare and apply for non-SCORE support at year 2 of the SC1 support and participate in a MORE-sponsored grant-writing workshop to facilitate grant-writing skills; and (3) initiate new research and educational programs at Howard University. The underlying theme of the proposed research is to reduce health disparities, to enhance excellence of research at Howard University and to permit my transition into an independent investigator. The proposed research may point to host CDK2 as a potential new target for anti-HIV-1 therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inhibition of HIV-1 in Sickle Cell Disease
-
批准号:9373638
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2016
-
负责人:SERGEI NEKHAI
-
依托单位:
Inhibition of HIV-1 in Sickle Cell Disease
-
批准号:8845248
-
项目类别:
-
资助金额:$37.18万
-
财政年份:2014
-
负责人:SERGEI NEKHAI
-
依托单位:
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African Americans
-
批准号:10359787
-
项目类别:
-
资助金额:$68.61万
-
财政年份:2014
-
负责人:SERGEI NEKHAI
-
依托单位:
Inhibition of HIV-1 in Sickle Cell Disease
-
批准号:9010978
-
项目类别:
-
资助金额:$43.32万
-
财政年份:2014
-
负责人:SERGEI NEKHAI
-
依托单位:
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African Americans
-
批准号:10589752
-
项目类别:
-
资助金额:$68.41万
-
财政年份:2014
-
负责人:SERGEI NEKHAI
-
依托单位:
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African Americans
-
批准号:10012487
-
项目类别:
-
资助金额:$71.82万
-
财政年份:2014
-
负责人:SERGEI NEKHAI
-
依托单位:
Inhibition of HIV-1 in Sickle Cell Disease
-
批准号:8732184
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2014
-
负责人:SERGEI NEKHAI
-
依托单位:
Center for Hemoglobin Research in Minorities (CHaRM)
-
批准号:9320021
-
项目类别:
-
资助金额:$142.82万
-
财政年份:2013
-
负责人:SERGEI NEKHAI
-
依托单位:
Regulation of HIV-1 Transcription by CDK2
-
批准号:7917823
-
项目类别:
-
资助金额:$20.6万
-
财政年份:2009
-
负责人:SERGEI NEKHAI
-
依托单位:
Regulation of HIV-1 Transcription by CDK2
-
批准号:7342549
-
项目类别:
-
资助金额:$25.9万
-
财政年份:2008
-
负责人:SERGEI NEKHAI
-
依托单位:
Regulation of HIV-1 Transcription by CDK2
-
批准号:7591241
-
项目类别:
-
资助金额:$25.9万
-
财政年份:2008
-
负责人:SERGEI NEKHAI
-
依托单位:
Regulation of HIV-1 Transcription by CDK2
-
批准号:8053393
-
项目类别:
-
资助金额:$25.64万
-
财政年份:2008
-
负责人:SERGEI NEKHAI
-
依托单位:
APPLICATION OF CELLULAR KINETICS AND MOLECULAR DYNAMICS
-
批准号:7561457
-
项目类别:
-
资助金额:$13.36万
-
财政年份:2007
-
负责人:SERGEI NEKHAI
-
依托单位:
REGULATION OF HIV-1 TRANSCRIPTION BY CDK2
-
批准号:6765864
-
项目类别:
-
资助金额:$27.42万
-
财政年份:2003
-
负责人:SERGEI NEKHAI
-
依托单位:
REGULATION OF HIV-1 TRANSCRIPTION BY CDK2
-
批准号:6696125
-
项目类别:
-
资助金额:$21.37万
-
财政年份:2003
-
负责人:SERGEI NEKHAI
-
依托单位:
REGULATION OF HIV-1 TRANSCRIPTION BY CDK2
-
批准号:6896629
-
项目类别:
-
资助金额:$0.61万
-
财政年份:2003
-
负责人:SERGEI NEKHAI
-
依托单位:
Howard University Research Scientist Award
-
批准号:7688011
-
项目类别:
-
资助金额:$25.6万
-
财政年份:1996
-
负责人:SERGEI NEKHAI
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: